Status:
UNKNOWN
Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients
Lead Sponsor:
Korea University Guro Hospital
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Pneumococcal Infections
Eligibility:
All Genders
70-75 years
Phase:
PHASE4
Brief Summary
Pneumococcal disease causes thousands of infections, such as meningitis, bloodstream infections, pneumonia, and ear infections in US annually. As pneumococcal vaccines provide serotype-specific protec...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Elderly people aged 70-75 years
- Had received PPSV23 in the previous 5-7 years
- Exclusion Criteria:
- Immunocompromised patients
- Subjects receiving immunosuppressive agents
- Subjects with a history of vaccination with pneumococcal conjugate vaccine
- Subjects with a history of pneumococcal disease (positive culture from blood or other sterile fluid)
- Fever (defined as an oral temperature \>37.5℃) within 24 h before PPSV23 vaccination
Exclusion
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2022
Estimated Enrollment :
254 Patients enrolled
Trial Details
Trial ID
NCT04875858
Start Date
May 1 2021
End Date
April 30 2022
Last Update
May 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Koera University Guro Hospital
Seoul, South Korea, 08308